CEL-SCI's L.E.A.P.S. Inventor Excited by H1N1 Treatment's Progress

• Press Release
• Source: BioMedReports.com
• On 9:54 am EDT, Tuesday October 20, 2009

LOS ANGELES--(BUSINESS WIRE)--BioMedReports.com, the news portal which covers Wall Street's biomedical sector and delivers financial and investment intelligence to a community of highly informed investors, has released an exclusive interview with Dr. Daniel Zimmerman of Cel-Sci Corporation (NYSE AMEX: CVM).

Related Quotes

Symbol	Price	Change
CVM	1.21	-0.04

{"s" : "cvm","k" : "c10,l10,p20,t10","o" : "","j" : ""}

It was this idea of taking several different interactions and training the immune response to be more specific to a medical need that led Zimmerman down the path towards developing L.E.A.P.S.™ - CEL-SCI's patented technology that is used to directly mimic cell/cell interactions on the T-cell surface with synthetic peptides. L.E.A.P.S.™ has also captured a great deal of attention in the area of H1N1, but details about the company's dealings with the U.S. Food and Drug Administration (FDA) and its first clinical trial to evaluate the effect of its investigational LEAPS-H1N1 treatment for hospitalized H1N1 patients have been hard to come by.

The complete exclusive interview is available now at BioMedReports.com.
http://biomedreports.com/articles/most-popular/13910-h1n1-program-is-qmoving-so-fastq.html

Biotech investors interested in accessing the news portal's complete database of clinical trials and upcoming FDA decisions can access that information here:
http://biomedreports.com/fda-calendar/fda-calendar.html

About BioMedReports.com

BioMedReports.com is a news portal covering the biomedical news and financial sector. BioMedReports is not paid, compensated or in any way incentivized to report news and developments about publicly traded companies.

For more biomedical sector and investment news go to http://BioMedReports.com.

BioMedReports.com
M. Davila, +1-323-472-4480
Editor
info@biomedreports.com
Fax: +1-888-210-3556